AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Association of Cognitive Impairment with Statin Use in Coronary Artery Disease Across APO (ε) Genotypes in AllofUS
By Hariharan P, Bagheri M, Sellke FW
BACKGROUND: Coronary artery disease (CAD) and Impaired Cognitive (IC) disease share sociodemographic, genetic, and clinical factors but the association of IC with statin use in CAD remains unclear. HYPOTHESIS: We hypothesized that IC is associated with statin use, and the effect could be modified based on sex, APO (ε) genotypes or lipid level changes in CAD. METHODS: We analyzed unique NIH AllofUS participants with CAD (age≥60 yrs) enrolled from 2017-2023 (Figure 1). We defined CAD as having a history of angina/myocardial infarction/chronic ischemic heart disease or having percutaneous coronary intervention/CABG, and IC as having mild cognitive impairment and all-cause dementia, defined using ICD/SNOMED codes. We assessed the association between IC and statin use using logistic regression analysis, while adjusting for clinical factors, sociodemographics, and APO (ε) genotypes before and after propensity score matching. We further performed stratified analysis by sex, and APO (ε) genotypes. We finally assessed the association between IC and statin users, based magnitude on the change in lipid levels before CAD and after IC (TC- Total cholesterol, LDL - low density lipoprotein, HDL- High Density Lipoprotein). We defined significance at p < 0.05. RESULTS: The cohort included 22,089 participants with CAD and 1343 with IC. Thirty-nine percent of participants were females, 77% were European, 13% were African American, and 9% were of Admixed American ancestry. The proportion of IC was higher ( 6.8% vs 3.5%, p<0.001 ) in statin users (n=17,191) vs non-statin users (n=4,898). IC was significantly associated with statin use ( OR:1.70;1.40-2.10, p = 4.9e-7 ) after adjustment for clinical factors, sociodemographics, and APO (ε) genotypes. After propensity-score matching between IC and CAD, we observed an association between IC and statin use ( OR:1.55;1.24-1.94, p =1e-4 ). In stratified analysis, the association between IC and statin use was strongest in the APO ε3/ε3 group ( OR:2.04;1.53-2.75, p = 1e-6 ), and in females ( OR:2.20;1.60-3.06, p = 2.e-6 ) compared to males ( OR:1.43;1.10-1.90, p = 0.01 ). While we did not observe any change in association between IC and statin use, based on the magnitude of decrease in TC and LDL levels, we observed an increased association between IC and statin users having higher HDL increase ( > 10 mg/dl: OR:1.95;1.44-2.66, p=1e-5 ) as compared to statin users with lesser HDL increase ( ≤ 10mg/dl: OR:1.61;1.22-2.15, p=8e-4 ). CONCLUSION: In the AllofUS cohort, IC was significantly associated with statin use in CAD participants. We observed the strongest association in the APO ε3ε3 group, among females, and with a greater increase in HDL levels in statin users.